Novo Nordisk lawsuit fails to halt Lilly obesity drug ads

A federal judge has denied Novo Nordisk's request to block Eli Lilly's advertising campaign comparing the obesity drugs Wegovy and Zepbound. The ruling allows Eli Lilly to continue its promotional efforts amid a high-stakes commercial battle in the projected $100 billion obesity medicine market.

Novo Nordisk sued Eli Lilly in July, alleging false advertising and unfair competition. The lawsuit claimed advertisements for Lilly's Zepbound and Mounjaro violated federal and state laws by comparing higher doses of Lilly's drugs to lower doses of Novo's Wegovy and Ozempic. Novo argued the ads used outdated studies and caused irreparable harm.

Court rejects preliminary injunction request

US District Judge Zahid Quraishi in Trenton, New Jersey, ruled that Novo Nordisk was not entitled to a preliminary injunction. The decision followed a two-day hearing in late August. The judge stated Novo Nordisk's claim of irreparable harm was 'inadequate to warrant the extraordinary relief it seeks.'

Judge Quraishi found that Novo failed to prove its case. He noted Wegovy prescription volume did not fall when the commercials aired and that the ads acknowledged the existence of a higher-dose Wegovy product. The judge described Novo Nordisk's case as 'less than persuasive' on a 'very preliminary record' and said the company could be made whole through monetary awards if no injunction were issued.

Evidence shows no market impact

Testimony during the hearing confirmed that prescriptions for Novo Nordisk's products held steady during the period the ads ran, from April to July. Lilly's U.S. finance chief Mark Stempel testified that Wegovy prescriptions remained stable. The judge found Eli Lilly's ads had at most a negligible market impact during that time.

In contrast, the ruling noted that Novo's U.S. vice president for obesity, Derrick Gastineau, had not attempted to determine any specific harm from the campaign. The judge also chastised Novo for its own advertising related to Ozempic, which claimed head-to-head superiority over Trulicity without revealing a higher-dose version's availability.

Market context and financial stakes

The legal dispute shows the intense competition in the rapidly growing obesity drug sector. Wall Street analysts expect the obesity medicine market to exceed $100 billion by 2030. Lilly's drug tirzepatide, sold as Zepbound for obesity and Mounjaro for diabetes, became the industry's best-selling product and helped Lilly become biopharma's first-ever trillion-dollar company. Novo's value has sputtered compared to Lilly's momentum.

Eli Lilly denied wrongdoing and welcomed the court's decision. The company had altered Zepbound ad language after a cease-and-desist letter to note the existence of high-dose Wegovy and specify it wasn't tested against Zepbound. A Novo spokesperson stated the ruling "does not decide the question of whether Lilly’s advertising is false and misleading," adding it only addresses whether an order will be issued at this early stage. Novo Nordisk may pursue monetary damages through ongoing litigation.